GV20 Therapeutics to Present at the Needham 23rd Annual Virtual Healthcare Conference

CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it will present at the Needham 23^rd Annual Virtual Healthcare Conference, taking place April 8-11, 2024.

Company management will also be conducting one-on-one meetings with investors at the conference.

ABOUT GV20 THERAPEUTICS

At GV20 Therapeutics, our mission is to develop a differentiated pipeline of innovative antibody therapeutics to transform cancer treatment.  We leverage our in-house STEAD platform (Simultaneous Target Evaluation and Antibody Discovery), which integrates AI, genomics, and disease biology to identify novel drug targets and create next-generation therapies against these targets.  Our lead program, GV20-0251, a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting a novel innate immune checkpoint IGSF8, is in a multi-center Phase I clinical trial in patients with advanced solid tumors (NCT05669430). GV20 is headquartered in Cambridge, MA. 

To learn more about GV20, please visit https://gv20tx.com/ and follow the company on LinkedIn.

Business Contact
Ying Gong, Ph.D., CBO
[email protected]

Investor and Media Contact
Amy Conrad
Juniper Point
[email protected]

SOURCE GV20 Therapeutics